23 November 2022

FAQs on the most important PRIIP requirements as of 01.01.2023

The provisions of Regulation (EU) No. 1286/2014 (PRIIPs Regulation) have been in force since 1 January 2018. Further details have been set out in regulatory technical standards in the form of Delegated Regulations (Regulation (EU) 2017/653, as most recently amended by Delegated Regulation (EU) 2021/2268).

The regulations concern what are known as packaged retail and insurance-based investment products (PRIIPs for short) and apply to all manufacturers and persons who advise on or sell them.

Exemptions currently still apply to the fund sector, but are set to expire at the end of 2022. From 1 January 2023, the PRIIPs rules will thus also be mandatory for the fund sector, which will entail some new challenges for funds and asset management companies as well as fund distributors.

Our GSK Update provides you with an overview of the key innovations that will apply from 2023 and that you should definitely be aware of in connection with the PRIIPs regulations.

Print


Press contact
presse@gsk.de
+49 30 203907-7763

Back

GSK Updates
  • 23 November 2022

    GSK Update: FAQs on the most important PRIIP requirements as of 01.01.2023

    Read more
  • 06 October 2022

    GSK Update: Real estate transfer tax on share deals – how to approach potential double taxation issues

    Read more
  • 26 August 2022

    GSK Update: How to do Compliance Risk Analysis

    Read more
Contact person

Philippe Lorenz

Local Partner*

+49 89 288174-662

philippe.lorenz@gsk.de

Lisa Baumann

Associate

+49 89 288174 95

lisa.baumann@gsk.de

For reasons of better readability, we use the gender-neutral generic masculine. However, the information expressly refers to all genders.

CO2 Neutral